HIV-1 Mutation L76V and Its Impact on Drug Susceptibility
Author Information
Author(s): Wiesmann Frank, Vachta Jan, Ehret Robert, Walter Hauke, Kaiser Rolf, Stürmer Martin, Tappe André, Däumer Martin, Berg Thomas, Naeth Gudrun, Braun Patrick, Knechten Heribert
Primary Institution: PZB Aachen, HIV&Hepatitis Research Group
Hypothesis
Does the L76V mutation in HIV-1 protease confer hypersusceptibility to protease inhibitors Atazanavir and Saquinavir?
Conclusion
Patients with the L76V mutation showed significantly higher long-term therapy success when treated with Atazanavir and/or Saquinavir compared to those without L76V-selecting agents.
Supporting Evidence
- The L76V mutation was associated with increased susceptibility to Atazanavir and Saquinavir.
- Phenotypic analysis showed full susceptibility for these drugs despite genotype-based predictions indicating resistance.
- Long-term therapy success was significantly higher in patients receiving L76V-selecting drugs.
Takeaway
Some HIV patients with a specific mutation (L76V) can actually respond better to certain medications, which is surprising because mutations usually make viruses harder to treat.
Methodology
The study analyzed genotypic and phenotypic resistance data from 47 L76V-positive patients and monitored their viral load over 96 weeks.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the reliance on online interpretation tools for resistance predictions.
Limitations
The study's small cohort size and the diversity of treatment regimens limit the generalizability of the findings.
Participant Demographics
The cohort consisted mostly of multi-resistant HIV-1 patients from Germany, with a majority being male.
Statistical Information
P-Value
0.002
Statistical Significance
p = 0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website